摘要
目的探讨分析利妥昔单抗联合CHOP方案治疗弥漫大B细胞性淋巴瘤的临床效果。方法选取该院住院治疗的弥漫大B细胞性淋巴瘤患者86例随机分成两组,其中给予利妥昔单抗与CHOP方案联合治疗的49例患者为实验组,剩下的37例仅用单纯的CHOP方案化疗的患者为对照组,两组患者在接受6个疗程的治疗后,对比两组的临床治疗效果。结果对照组有效率为86.49%,实验组有效率达到93.88%,明显高于对照组(P<0.05)。结论利妥昔单抗与CHOP方案联合治疗弥漫大B细胞性淋巴瘤临床效果显著,值得临床上进一步推广应用。
Objective To investigate and analyse rituximab combination with CHOP in patients with diffuse large B-cell lymphoma clinical effect. Method Select 86 cases of diffuse large B-cell lymphoma patients treatment in our hospital, randomly divided into two groups, which given rituximab with CHOP regimen combined treatment of 49 patients for the experimental group, and the remaining 37 cases only pure CHOP chemotherapy patients as the control group, the two groups of patients received six courses of treatment, the clinical effect of the two groups were compared. Results The control group efficiency was 86.49%, the experimental group efficiency of 93.88%, significantly higher than the control group （P 〈 0.05 ）. Conclusion Rituximab and CHOP regimen combined treatment of diffuse large B-cell lymphoma significant clinical effect, it is worth further promote in the use of clinical.
出处
《中国卫生产业》
2012年第34期20-21,共2页
China Health Industry
